Kiadis completes end-of-Phase II meeting on Reviroc
This article was originally published in Pharmaceutical Approvals Monthly
FDA has agreed that data from the completed Phase II trial of Kiadis Pharma's Reviroc supports moving the drug into Phase III, the company announces Dec. 19 after completing an end-of-Phase II meeting with FDA. Reviroc, used to eliminate cancer cells from autologous grafts in bone marrow transplants for end-stage blood cancer patients, improved overall survival in non-Hodgkin's lymphoma patients after transplantation in a Phase II trial. The Phase III trial will focus on patients with large B cell lymphoma and will be designed under a special protocol assessment with FDA...
You may also be interested in...
A trio of newly finalized guidance documents from the US agency dated 25 September explain how the Accreditation Scheme for Conformity Assessment pilot will work, and what biocompatibility and safety standards will apply.
Approval of Alaway Preservative Free (ketotifen fumarate, 0.035) comes 15 months after FDA submitted a complete response letter to Bausch and the active ingredient developer, Eton Pharmaceuticals.
Unfounded expectation some firms have for FDA to protect their investments in preparing successful NDI notifications is part of industry’s overall interest in increased regulation of the market, says Steven Tave, Office of Dietary Supplement Programs director.